| Time | Presentation | Presenter/Lab |
|---|---|---|
| 8:50 a.m. | Introduction to the Annual CPT Symposium | Joseph Balthasar |
| 9:00 a.m. | Hepatic FcRn and the Impact of its Loss on FcRn-Mediated Recycling | Marilyn Morris |
| 9:30 a.m. | BCSFB transport and disposition of IgG1 | Marilyn Morris |
| 10:00 a.m. | Evaluation of Brain Pharmacokinetics of Protein Therapeutics after Local Administration | Dhaval Shah |
| 10:30 a.m. | Break | |
| 11:00 a.m. | Evaluation of CAR-Bomb strategies for targeted delivery of anti-cancer siRNA | Joseph Balthasar |
| 11:30 a.m. | Study viable approaches for oral delivery of colon‐targeting macromolecules (e.g. targeting TNF for and the gut absorption mechanism following oral delivery | Sathy Balu-Iyer |
| 12:00 p.m. | Break | |
| 12:30 p.m. | Evaluation of the effects of cell penetrating peptides and endosomal escape peptides on the pharmacokinetics of anti-cancer monoclonal antibodies | Joseph Balthasar |
| 1:00 p.m. | Evaluation of the therapeutic selectivity of anti-CEA SN38 antibody-drug conjugates (ADC) and antibody drug fragment complexes (FDC) | Joseph Balthasar |
| 1:30 p.m. | Effect of Charge Variation on the Disposition of Monoclonal Antibodies | Dhaval Shah |
| 2:00 p.m. | Break | |
| 2:30 p.m. | 3D-printed micro scaffold for high-resolution tissue compartmentalization / micro-sampling and application in measuring the tissue distribution of protein biotherapeutics and biomarkers | Jun Qu |
| 3:00 p.m. | Evaluation of pH Dependent Antigen Binding and Geldanamycin Co-administration as Novel Strategies for Enhanced Intracellular Delivery of Antibody-Drug Conjugates (ADCs) | Dhaval Shah |
| 3:30 p.m. | Liposomal IL-12 protects melanoma patient-derived tumor-specific T cells from an up regulation of PD-1, exhaustion and loss of function following their adoptive transfer and entry into the tumor microenvironment of melanoma tumor xenografts | Donald Mager |
| 4:00 p.m. | Concluding Remarks | Joseph Balthasar |
| Time | Presentation |
|---|---|
| 8:30 a.m. | Registration / Coffee |
| 8:55 a.m. | Introduction to the Eleventh Annual Symposium (Dr. J. Balthasar) |
| 9:00 a.m. | Sensitive, accurate investigation of biotherapeutics and biomarker/target levels in both fresh and FFPE tissues, and application in Inflammatory bowel diseases (Qu Lab) |
| 9:30 a.m. | Extensive investigation of ocular tissue disposition of antibody-drug conjugates (Qu Lab) |
| 10:00 a.m. | Study viable approaches for oral delivery of colon-targeting macromolecules (e.g. targeting TNF for IBD), and understand the gut absorption mechanism following oral delivery (Balu-Iyer Lab) |
| 10:30 a.m. | Break |
| 11:00 a.m. | Tumor selectivity of anti-carcinoembryonic antigen scFv, scFv-ABD, and monoclonal antibodies in a mouse model of human colorectal cancer (J. Ryan Polli, Balthasar Lab) |
| 11:30 a.m. | PK/PD Modeling of Liposomal IL-12 Enhancement of Human Tumor-Specific T Cell Killing (Mager Lab) |
| 12:00 p.m. | Lunch |
| 1:30 p.m. | Brain Pharmacokinetics of Different Size Antibody Fragments (Shah Lab) |
| 2:00 p.m. | Clinical Validation of Antibody PBPK Model Using 89Zr Labelled Imaging Studies (Shah Lab) |
| 2:30 p.m. | BCSFB transport of protein therapeutics: Influence of Type 2 Diabetes (Morris Lab) |
| 3:00 p.m. | Break |
| 3:20 p.m. | Dynamic contrast enhanced magnetic resonance imaging for the prediction of monoclonal antibody tumor disposition (Brandon Bordeau, Balthasar Lab) |
| 3:50 p.m. | Multiparametric MRI-based physiological imaging to predict mAb penetration and efficacy in pancreatic cancer (Straubinger Lab) |
| 4:20 p.m. | Visualizing the Renal Disposition of Proteins and Peptides using Two-Photon Microscopy (Morris Lab) |
| 4:50 p.m. | Concluding Remarks (J. Balthasar) |
